Involvement of matrix metalloproteinases-2 and -9 in the formation of a lacuna-like cerebral cavity

Journal of Neuroscience Research

Volumn 91, Issue 7, 2013, Pages 920-933

  Cayabyab, Francisco S ^a   Gowribai, Krishnamoorty ^b   Walz, Wolfgang ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Confocal microscopy; Glial cell response to injury; In vivo studies; Inflammation; Ischemia

Indexed keywords

BATIMASTAT; ED1 PROTEIN; GELATINASE A; GELATINASE B; MINOCYCLINE; OX 42 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN VENTRICLE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME RELEASE; IMMUNOPRECIPITATION; MACROPHAGE; MALE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; UPREGULATION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; DISEASE MODELS, ANIMAL; ECTODYSPLASINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICROGLIA; MINOCYCLINE; PHENYLALANINE; PROTEASE INHIBITORS; RATS; RATS, WISTAR; STROKE; STROKE, LACUNAR; THIOPHENES; TIME FACTORS;

EID: 84877925667     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23223     Document Type: Article

References (45)

1. Amantea D, Corasaniti MT, Mercuri NB, Bernardi G, Bagetta G. 2008. Brain regional and cellular localization of gelatinase activity in rat that have undergone transient middle cerebral artery occlusion. Neuroscience 152:8-17.
2. Aparicio T, Kermorgant S, Dessirier V, Lewin MJ, Lehy T. 1999. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 20:1445-1451.
3. Arai K, Lee SR, Lo EH. 2003. Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. Glia 43:254-264.
4. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. 2000. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681-1689.
5. Bolte S, Cordelieres FP. 2006. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224:213-232.
6. Brust TB, Cayabyab FS, Zhou N, MacVicar BA. 2006. p38 Mitogen-activated protein kinase contributes to adenosine A1 receptor-mediated synaptic depression in area CA1 of the rat hippocampus. J Neurosci 26:12427-12438.
7. Brust TB, Cayabyab FS, MacVicar BA. 2007. C-Jun N-terminal kinase regulates adenosine A1 receptor-mediated synaptic depression in the rat hippocampus. Neuropharmacology 53:906-917.
8. Candelario-Jalil E, Yang Y, Rosenberg GA. 2009. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158:983-994.
9. Chang DI, Hosomi N, Lucero J, Heo JH, Abumiya T, Mazar AP, del Zoppo GJ. 2003. Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab 23:1408-1419.
10. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. 2005. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 25:9275-9284.
11. Das RR, Seshadri S, Beiser AS, Kelly-Hayes M, Au R, Himali JJ, Kase CS, Benjamin EJ, Polak JF, O'Donnell CJ, Yoshita M, D'Agostino RB Sr, DeCarli C, Wolf PA. 2008. Prevalence and correlates of silent cerebral infarcts in the Framingham Offspring Study. Stroke 39:2929-2935.
12. del Zoppo GJ. 2010. The neurovascular unit, matrix proteases, and innate inflammation. Ann N Y Acad Sci 1207:46-49.
13. del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, Koziol JA. 2007. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 38(Suppl 2):646-651.
14. Dheen ST, Kaur C, Ling EA. 2007. Microglial activation and its implications in the brain diseases. Curr Med Chem 14:1189-1197.
15. Ethell IM, Ethell DW. 2007. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res 85:2813-2823.
16. Fatar M, Stroick M, Griebe M, Hennerici M. 2005. Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 20:141-151.
17. Greenberg SM. 2006. Small vessels, big problems. N Engl J Med 354:1451-1453.
18. Hailer NP. 2008. Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog Neurobiol 84:211-233.
19. Hainsworth AH, Markus HS. 2008. Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J Cereb Blood Flow Metab 28:1877-1891.
20. Hua R, Walz W. 2006a. Minocycline treatment prevents cavitation in rats after a cortical devascularizing lesion. Brain Res 1090:172-181.
21. Hua R, Walz W. 2006b. The need for animal models in small-vessel brain disease. Crit Rev Neurobiol 18:5-11.
22. Huntley GW. 2012. Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci 13:743-757.
23. Kim YS, Lee KY, Koh SH, Park CY, Kim HY, Lee YJ, Kim HT, Kim J, Kim MH, Kim KS, Chang DI, Kim SH. 2006. The role of matrix metalloproteinase 9 in early neurological worsening of acute lacunar infarction. Eur Neurol 55:11-15.
24. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, Opdenakker G, Koistinaho J. 2005. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab 25:460-467.
25. Lammie GA. 2000. Pathology of small vessel stroke. Br Med Bull 56:296-306.
26. Lovett DH, Mahimkar R, Raffai RL, Cape L, Maklashina E, Cecchini G, Karliner JS. 2012. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 7:e34177.
27. Lucivero V, Prontera M, Mezzapesa DM, Petruzzellis M, Sancilio M, Tinelli A, Di Noia D, Ruggieri M, Federico F. 2007. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol Sci 28:165-170.
28. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. 2006. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci 7:56.
29. McColl BW, Rose N, Robson FH, Rothwell NJ, Lawrence CB. 2010. Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke. J Cereb Blood Flow Metab 30:267-272.
30. Paemen L, Martens E, Norga K, Masure S, Roets E, Hoogmartens J, Opdenakker G. 1996. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 52:105-111.
31. Pereira AM, Strasberg-Rieber M, Rieber M. 2005. Invasion-associated MMP-2 and MMP-9 are up-regulated intracellularly in concert with apoptosis linked to melanoma cell detachment. Clin Exp Metast 22:285-295.
32. Planas AM, Sole S, Justicia C. 2001. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 8:834-846.
33. Price TR, Manolio TA, Kronmal RA, Kittner SJ, Yue NC, Robbins J, Anton-Culver H, O'Leary DH. 1997. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke 28:1158-1164.
34. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. 2001. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem 8:305-316.
35. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC. 2005. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 288:F91-F97.
36. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. 2002. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 33:21-25.
37. Wang K, Walz W. 2003. Unusual topographical pattern of proximal astrogliosis around a cortical devascularizing lesion. J Neurosci Res 73:497-506.
38. Wharton SB, Lammie GA, Collie DA, Whittle IR. 2000. The significance of intratumoural neurones and neuronal differentiation in diffuse gliomas: a case series. Acta Neuropathol 100:695-700.
39. Wojtowicz T, Mozrzymas JW. 2010. Late phase of long-term potentiation in the mossy fiber-CA3 hippocampal pathway is critically dependent on metalloproteinases activity. Hippocampus 20:917-921.
40. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ. 1996. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14:193-202.
41. Wright JW, Brown TE, Harding JW. 2007. Inhibition of hippocampal matrix metalloproteinase-3 and -9 disrupts spatial memory. Neural Plast 2007:73813.
42. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. 2007. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27:697-709.
43. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. 1998. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95:15769-15774.
44. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH. 2006. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12:441-445.
45. Zinchuk V, Grossenbacher-Zinchuk O. 2009. Recent advances in quantitative colocalization analysis: focus on neuroscience. Prog Histochem Cytochem 44:125-172.